Purpose of review In recent years, traditional b-lactams have dramatically reduced their effectiveness against gram-negative bacteria mainly because of their ability to express multiple b-lactamase or carabapenemases that are not hydrolyzed by the old b-lactam inhibitors (BLIs) such as clavulanic acid, tazobactam, and sulbactam. New BLIs molecules have been developed to face the need of compounds that are active against multidrug or pandrug resistant gram-negative pathogens. The aim of this review is to summarize the new generation of BLIs and b-lactams combinations. Recent findings A number of new molecules with activity against Ambler class A (e.g., extended-spectrum b-lactamases, serine carbapenemases), class C (e.g., AmpC), or class D (e.g., oxacillinase-48) have been recently approved in combination with old b-lactams for the treatment of multidrug-resistant bacteria, and other agents are under investigation. These new compounds include diazabicyclooctanones non-b-lactam inhibitors (e.g., avibactam, relebactam, nacubactam) and boronic acid inhibitors (e.g., vaborbactam). Summary Newly approved and investigational new BLIs are expected to offer many advantages for the management of patients with multidrug-resistant gram-negative pathogens. Promising characteristics of new compounds include high activity against multi drug resistance gram-negative bacteria and a favorable safety profile.

The role of new β-lactamase inhibitors in gram-negative infections

Vena A.;Bassetti M.
2019-01-01

Abstract

Purpose of review In recent years, traditional b-lactams have dramatically reduced their effectiveness against gram-negative bacteria mainly because of their ability to express multiple b-lactamase or carabapenemases that are not hydrolyzed by the old b-lactam inhibitors (BLIs) such as clavulanic acid, tazobactam, and sulbactam. New BLIs molecules have been developed to face the need of compounds that are active against multidrug or pandrug resistant gram-negative pathogens. The aim of this review is to summarize the new generation of BLIs and b-lactams combinations. Recent findings A number of new molecules with activity against Ambler class A (e.g., extended-spectrum b-lactamases, serine carbapenemases), class C (e.g., AmpC), or class D (e.g., oxacillinase-48) have been recently approved in combination with old b-lactams for the treatment of multidrug-resistant bacteria, and other agents are under investigation. These new compounds include diazabicyclooctanones non-b-lactam inhibitors (e.g., avibactam, relebactam, nacubactam) and boronic acid inhibitors (e.g., vaborbactam). Summary Newly approved and investigational new BLIs are expected to offer many advantages for the management of patients with multidrug-resistant gram-negative pathogens. Promising characteristics of new compounds include high activity against multi drug resistance gram-negative bacteria and a favorable safety profile.
File in questo prodotto:
File Dimensione Formato  
Bassetti2019_The role of new β-lactamase.pdf

accesso chiuso

Tipologia: Documento in versione editoriale
Dimensione 314.72 kB
Formato Adobe PDF
314.72 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/986092
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 22
social impact